S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
New CBOE “special perk” helps traders target income every weekend (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
New CBOE “special perk” helps traders target income every weekend (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
New CBOE “special perk” helps traders target income every weekend (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
The truth about DocuSign's relevancy in today's world: Surprise
New CBOE “special perk” helps traders target income every weekend (Ad)
SoFi expands ETF business with options-driven income fund
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company

Augmedix Stock Price, News & Analysis (OTCMKTS:AUGX)

$5.63
-0.01 (-0.18%)
(As of 12/5/2023 ET)
Compare
Today's Range
$5.55
$5.71
50-Day Range
$4.34
$5.72
52-Week Range
$1.01
$5.97
Volume
212,614 shs
Average Volume
442,035 shs
Market Capitalization
$232.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.83

Augmedix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
21.4% Upside
$6.83 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.48) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.48 out of 5 stars


AUGX stock logo

About Augmedix Stock (OTCMKTS:AUGX)

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Notes that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, a self-service mobile software application. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

AUGX Stock Price History

AUGX Stock News Headlines

Augmedix, Inc. (AUGX)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Why Is Augmedix (AUGX) Stock Down 27% Today?
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Are Medical Stocks Lagging Augmedix (AUGX) This Year?
B.Riley Financial Keeps Their Buy Rating on Augmedix (AUGX)
Why Shares of Augmedix Are Climbing on Tuesday
Augmedix's Earnings: A Preview
See More Headlines
Receive AUGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Health Information Services
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:AUGX
Fax
N/A
Employees
1,040
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.83
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+21.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-24,450,000.00
Pretax Margin
-57.23%

Debt

Sales & Book Value

Annual Sales
$40.93 million
Book Value
$0.10 per share

Miscellaneous

Free Float
36,316,000
Market Cap
$232.88 million
Optionable
Not Optionable
Beta
-0.15
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Emmanuel Krakaris (Age 64)
    President, CEO, Secretary & Director
    Comp: $734.33k
  • Mr. Ian Shakil (Age 38)
    Founder, Chief Strategy Officer & Director
  • Ms. Sandra Breber (Age 65)
    Chief Operating Officer
    Comp: $446.05k
  • Mr. Saurav Chatterjee Ph.D. (Age 51)
    Chief Technology Officer
    Comp: $438.05k
  • Mr. Paul Louis Ginocchio (Age 53)
    Chief Financial Officer
  • Todd Holvick
    Head of Legal & Compliance
  • Lia Wallick
    Head of People
  • Dr. Davin Lundquist M.D.
    Chief Medical Officer
  • Mr. Jonathan Hawkins (Age 53)
    Chief Revenue Officer
    Comp: $417.71k














AUGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Augmedix stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Augmedix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AUGX shares.
View AUGX analyst ratings
or view top-rated stocks.

What is Augmedix's stock price target for 2024?

3 equities research analysts have issued 1-year price targets for Augmedix's stock. Their AUGX share price targets range from $6.00 to $8.00. On average, they anticipate the company's stock price to reach $6.83 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price.
View analysts price targets for AUGX
or view top-rated stocks among Wall Street analysts.

How have AUGX shares performed in 2023?

Augmedix's stock was trading at $1.56 at the beginning of 2023. Since then, AUGX stock has increased by 260.9% and is now trading at $5.63.
View the best growth stocks for 2023 here
.

How were Augmedix's earnings last quarter?

Augmedix, Inc. (OTCMKTS:AUGX) released its quarterly earnings data on Monday, November, 6th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. The business had revenue of $11.77 million for the quarter, compared to analysts' expectations of $11.41 million. Augmedix had a negative net margin of 57.70% and a negative trailing twelve-month return on equity of 980.09%.

How do I buy shares of Augmedix?

Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:AUGX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -